{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:32:05Z","timestamp":1774553525440,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"am","delay-in-days":303,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.neuropharm.2023.109733","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T19:27:27Z","timestamp":1697311647000},"page":"109733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Fluoroethylnormemantine (FENM) shows synergistic protection in combination with a sigma-1 receptor agonist in a mouse model of Alzheimer's disease"],"prefix":"10.1016","volume":"242","author":[{"given":"Aline","family":"Freyssin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Carles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6114-0209","authenticated-orcid":false,"given":"Sarra","family":"Guehairia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Rubinstenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-6793","authenticated-orcid":false,"given":"Tangui","family":"Maurice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109733_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009775","article-title":"Cardiac dysfunction in the sigma 1 receptor knockout mouse associated with impaired mitochondrial dynamics and bioenergetics","volume":"7","author":"Abdullah","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.neuropharm.2023.109733_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neuroscience.2018.01.041","article-title":"The protective effects of IGF-I against \u03b2-Amyloid-related downregulation of hippocampal somatostatinergic system involve activation of akt and protein kinase A","volume":"374","author":"Aguado-Llera","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109733_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/brainsci12050577","article-title":"Is L-glutamate toxic to neurons and thereby contributes to neuronal loss and neurodegeneration? A systematic review","volume":"12","author":"Al-Nasser","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2023.109733_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.1995.tb17464.x","article-title":"Nicotinic receptor function in the mammalian central nervous system","volume":"757","author":"Albuquerque","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2023.109733_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10799899909036640","article-title":"Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor","volume":"19","author":"Ametamey","year":"1999","journal-title":"J. Recept. Signal Transduct. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109733_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1345\/aph.17150","article-title":"Donepezil use in Alzheimer disease","volume":"32","author":"Barner","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2023.109733_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejphar.2006.06.045","article-title":"Altered synaptic function in Alzheimer's disease","volume":"545","author":"Bell","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1017\/S135561771700100X","article-title":"Alzheimer's disease: past, present, and future","volume":"23","author":"Bondi","year":"2017","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.neuropharm.2023.109733_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2023.109733_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00023210-200317090-00004","article-title":"The glutamatergic system and Alzheimer's disease: therapeutic implications","volume":"17","author":"Butterfield","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2023.109733_bib12","first-page":"303","article-title":"Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics","volume":"3","author":"Cacabelos","year":"2007","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2023.109733_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neurobiolaging.2018.08.024","article-title":"Early disruption of parvalbumin expression and perineuronal nets in the hippocampus of the Tg2576 mouse model of Alzheimer's disease can be rescued by enriched environment","volume":"72","author":"Cattaud","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2023.109733_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ijnp\/pyab007","article-title":"Fluoroethylnormemantine, a novel derivative of memantine, facilitates extinction learning without sensorimotor deficits","volume":"24","author":"Chen","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.biopsych.2021.04.024","article-title":"Fluoroethylnormemantine, a novel NMDA receptor antagonist, for the prevention and treatment of stress-induced maladaptive behavior","volume":"90","author":"Chen","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109733_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/cells8030211","article-title":"Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo","volume":"8","author":"Christ","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2023.109733_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/ijnp\/pyaa075","article-title":"Anti-Amnesic and neuroprotective effects of Fluoroethylnormemantine in a pharmacological mouse model of Alzheimer's disease","volume":"24","author":"Couly","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh3763","article-title":"Activation of the sigma-1 receptor chaperone alleviates symptoms of Wolfram syndrome in preclinical models","volume":"14","author":"Crouzier","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2023.109733_bib19","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/gps.938","article-title":"The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence","volume":"18","author":"Danysz","year":"2003","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109733_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000440864","article-title":"AF710B, a novel M1\/\u03c31 agonist with therapeutic efficacy in animal models of Alzheimer's disease","volume":"16","author":"Fisher","year":"2016","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2023.109733_bib21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.2.618.485","article-title":"Lecture on the antagonism between the actions of active substances","volume":"2","author":"Fraser","year":"1872","journal-title":"Br. Med. J."},{"key":"10.1016\/j.neuropharm.2023.109733_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12640-017-9838-2","article-title":"Sigma-1 receptor agonists induce oxidative stress in mitochondria and enhance complex I activity in physiological condition but protect against pathological oxidative stress","volume":"35","author":"Goguadze","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2023.109733_bib23","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/ijms18081813","article-title":"Towards a better understanding of GABAergic remodeling in alzheimer's disease","volume":"18","author":"Govindpani","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109733_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1831","article-title":"Or combination therapy-what is the best therapy for Alzheimer's disease? A Network Meta-Analysis","volume":"10","author":"Guo","year":"2020","journal-title":"Brain Behav"},{"key":"10.1016\/j.neuropharm.2023.109733_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113344","article-title":"Stimulation of astrocytic sigma-1 receptor is sufficient to ameliorate inflammation- induced depression","volume":"410","author":"Guo","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109733_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1167\/iovs.10-5731","article-title":"Sigma receptor 1 modulates endoplasmic reticulum stress in retinal neurons","volume":"52","author":"Ha","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.neuropharm.2023.109733_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jalz.2017.11.009","article-title":"AF710B, an M1\/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease","volume":"14","author":"Hall","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2023.109733_bib28","article-title":"A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study","volume":"6","author":"Hampel","year":"2020","journal-title":"Alzheimers Dement (NY)"},{"key":"10.1016\/j.neuropharm.2023.109733_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109733_bib30","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3565(24)39299-7","article-title":"Ca2+ signaling via sigma1-receptors: novel regulatory mechanism affecting intracellular Ca2+ concentration","volume":"293","author":"Hayashi","year":"2000","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109733_bib31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2023.109733_bib32","doi-asserted-by":"crossref","first-page":"7916","DOI":"10.1073\/pnas.1300677110","article-title":"Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models","volume":"110","author":"Hedskog","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2023.109733_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbrc.2019.08.025","article-title":"Neuroprotective effects of memantine via enhancement of autophagy","volume":"518","author":"Hirano","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2023.109733_bib34","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/0024-3205(94)00384-X","article-title":"Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis","volume":"55","author":"Ingram","year":"1994","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2023.109733_bib35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1027376230898","article-title":"Cholinergic neurotransmission and synaptic plasticity concerning memory processing","volume":"22","author":"Jerusalinsky","year":"1997","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2023.109733_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(98)00943-4","article-title":"TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons","volume":"260","author":"Kato","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2023.109733_bib37","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"NC3Rs Reporting Guidelines Working Group. Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113409","article-title":"Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond","volume":"293","author":"Koola","year":"2020","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109733_bib39","first-page":"91","article-title":"Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties","volume":"43","author":"Kornhuber","year":"1994","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1016\/j.neuropharm.2023.109733_bib40","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4103\/1673-5374.301009","article-title":"The effects of amyloid-beta on hippocampal glutamatergic receptor and transporter expression","volume":"16","author":"Kwakowsky","year":"2021","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.neuropharm.2023.109733_bib41","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1038\/s41467-020-19396-3","article-title":"Sigma-1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Drosophila ALS\/FTD models","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2023.109733_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105857","article-title":"Pridopidine rescues BDNF\/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model","volume":"173","author":"Lenoir","year":"2022","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109733_bib43","doi-asserted-by":"crossref","first-page":"E1279","DOI":"10.1073\/pnas.1714409115","article-title":"Intracellular Ca2+ stores control in vivo neuronal hyperactivity in a mouse model of Alzheimer's disease","volume":"115","author":"Lerdkrai","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2023.109733_bib44","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1096\/fj.08-107268","article-title":"Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors","volume":"22","author":"L\u00e9veill\u00e9","year":"2008","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2023.109733_bib45","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/cns.12768","article-title":"Sigma-1 receptor agonist increases axon outgrowth of hippocampal neurons via voltage-gated calcium ions channels","volume":"23","author":"Li","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2023.109733_bib46","series-title":"Top Line Data of ANAVEX\u00ae2-73 (Blarcamesine) Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 2b\/3 in Patients with Early Alzheimer's Disease (AD)","author":"Macfarlane","year":"2022"},{"key":"10.1016\/j.neuropharm.2023.109733_bib47","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1111\/bph.13076","article-title":"The effects of sigma (\u03c31) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice","volume":"172","author":"Malik","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108526","article-title":"Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivo","volume":"127","author":"Martin","year":"2022","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2023.109733_bib49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1113\/jphysiol.2006.116178","article-title":"The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus","volume":"578","author":"Martina","year":"2007","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-3-319-50174-1_15","article-title":"Role of \u03c31 receptors in learning and memory and alzheimer's disease-type dementia","volume":"964","author":"Maurice","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0006-8993(94)91397-8","article-title":"Behavioral evidence for a modulating role of sigma ligands in memory processes. I. Attenuation of dizocilpine (MK-801)-induced amnesia","volume":"647","author":"Maurice","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109733_bib52","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-8993(95)01032-7","article-title":"Amnesia induced in mice by centrally administered \u03b2-amyloid peptides involves cholinergic dysfunction","volume":"706","author":"Maurice","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109733_bib53","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/jpet.105.097394","article-title":"Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil","volume":"317","author":"Maurice","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109733_bib54","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0091-3057(94)90235-6","article-title":"PRE-084, a sigma selective PCP derivative, attenuates MK-801-induced impairment of learning in mice","volume":"49","author":"Maurice","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109733_bib56","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/17460441.2021.1838483","article-title":"Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders","volume":"16","author":"Maurice","year":"2021","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109733_bib57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.bbr.2015.09.020","article-title":"Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments","volume":"296","author":"Maurice","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109733_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2013.08.013","article-title":"Dysfunctional synapse in Alzheimer's disease - a focus on NMDA receptors","volume":"76","author":"Mota","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109733_bib59","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bcp.2015.07.022","article-title":"Alpha7 nicotinic receptor activation protects against oxidative stress via heme-oxygenase I induction","volume":"97","author":"Navarro","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib60","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/jnc.12319","article-title":"Neuroprotective effects of donepezil against A\u03b242-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3\u03b2 and nAChRs activity","volume":"127","author":"Noh","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2023.109733_bib61","article-title":"Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia","volume":"2","author":"Parsons","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2023.109733_bib62","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1124\/mol.116.105130","article-title":"GluN2D-Containing N-methyl-d-Aspartate receptors mediate synaptic transmission in hippocampal interneurons and regulate interneuron activity","volume":"90","author":"Perszyk","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/psyg.12944","article-title":"Aducanumab for the treatment of Alzheimer's disease: a systematic review","author":"Rahman","year":"2023","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.neuropharm.2023.109733_bib64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"European Huntington's disease network; Huntington study group investigators. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.nbd.2018.12.022","article-title":"Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor","volume":"124","author":"Ryskamp","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2023.109733_bib66","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nucmedbio.2015.04.001","article-title":"Radiolabeling of [18F]-fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors","volume":"42","author":"Salabert","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.12.003","article-title":"Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats","volume":"59","author":"Salabert","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib68","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0969-8051(98)00003-1","article-title":"Electrophysiological study, biodistribution in mice, and preliminary PET evaluation in a rhesus monkey of 1-amino-3-[18F]fluoromethyl-5-methyl-adamantane (18F-MEM): a potential radioligand for mapping the NMDA-receptor complex","volume":"25","author":"Samnick","year":"1998","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib69","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","article-title":"Galantamine: a review of its use in Alzheimer's disease","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2023.109733_bib70","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1021\/acschemneuro.7b00329","article-title":"A novel negative allosteric modulator selective for GluN2C\/2D-Containing NMDA receptors inhibits synaptic transmission in hippocampal interneurons","volume":"9","author":"Swanger","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109733_bib71","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1124\/jpet.102.041970","article-title":"Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants","volume":"303","author":"Takebayashi","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109733_bib72","unstructured":"Tsai SY, Chuang JY, Tsai MS, Wang XF, Xi ZX, Hung JJ, Chang WC, Bonci A, Su TP. Sigma-1 receptor mediates cocaine-induced transcriptional regulation by recruiting chromatin-remodeling factors at the nuclear envelope. Proc. Natl. Acad. Sci. U.S.A.. 2015112:E6562-E6570. doi: 10.1073\/pnas.1518894112.."},{"key":"10.1016\/j.neuropharm.2023.109733_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109733_bib74","doi-asserted-by":"crossref","first-page":"32","DOI":"10.17116\/jnevro201811806232","volume":"118","author":"Vasenina","year":"2018","journal-title":"Zh. Nevrol. Psikhiatr. Im. S S Korsakova"},{"key":"10.1016\/j.neuropharm.2023.109733_bib75","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/npp.2008.212","article-title":"Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid \u03b225-35-induced toxicity in mice","volume":"34","author":"Villard","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109733_bib76","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0269881110379286","article-title":"Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor\/sigma 1 (\u03c31) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative","volume":"25","author":"Villard","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1094356","article-title":"Mitochondrial calcium cycling in neuronal function and neurodegeneration","volume":"11","author":"Walters","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2023.109733_bib78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0304-3940(99)00567-4","article-title":"Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex","volume":"272","author":"Wang","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2023.109733_bib79","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0024-3205(00)00411-2","article-title":"No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use","volume":"66","author":"Wenk","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2023.109733_bib80","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0","article-title":"Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)","volume":"14","author":"Winblad","year":"1999","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109733_bib81","doi-asserted-by":"crossref","first-page":"11246","DOI":"10.1523\/JNEUROSCI.2488-10.2010","article-title":"Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses","volume":"30","author":"Xia","year":"2010","journal-title":"J. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823003234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823003234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:27:13Z","timestamp":1758439633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823003234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":80,"alternative-id":["S0028390823003234"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109733","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluoroethylnormemantine (FENM) shows synergistic protection in combination with a sigma-1 receptor agonist in a mouse model of Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109733"}}